Single-Use Bioreactor Sterilization Patents: Who Holds the Ground and Where It's Still Open
Concentrated at the top. The five leading assignees together hold 140 of 222 records in scope (63.1%), and the top ten account for 200 (90.1%) — a field with little room for a new entrant to out-file the incumbents head-on. Filings rose from 13 in 2017 to a peak of 64 in 2023, then held flat between 2021 and 2024 (4 to 4, 0% change) before the most recent two years understate true activity due to publication lag — treat 2025 and 2026 as incomplete, not as a downturn.
- 1REGENERON PHARMACEUTICALS INC54
- 2EMD MILLIPORE CORP27
- 3JUST EVOTEC BIOLOGICS INC26
- 4MERCK SHARP & DOHME CORP18
- 5GEOSYNFUELS LLC15
See the full single-use bioreactor sterilization analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on single-use bioreactor sterilization patents
Who are the leading patent holders in single-use bioreactor sterilization?
The ranked list covers 52 assignees across 222 records, and it is heavily front-loaded: the leading assignee holds 54 records, more than three times the count at fifth place (15). The top five assignees together account for 63.1% of all 222 records in scope, and the top ten reach 90.1%. That concentration means due diligence on this space should focus on a small number of incumbent portfolios rather than a broad field of near-equal competitors.
Is filing activity in this field growing or slowing down?
Filings were flat between 2021 and 2024, holding at 4 records in each of those years for 0% change, after peaking at 64 records in 2023. The 2025 and 2026 figures look lower, but that is a publication-lag artifact: patent applications typically publish around 18 months after filing, so the most recent two years are still filling in and should not be read as a real decline.
What technology areas overlap most with bioreactor sterilization claims?
Sterilization claims in this set are frequently bundled with downstream biological processing. C07K (peptides and proteins) appears in 37.8% of the 222 records, B01D (separation and filtration processes) in 19.4%, and C12P (fermentation and enzymatic synthesis) in 18.5%. Because a single record can carry multiple IPC classes, these shares sum to more than 100%, but the pattern is clear: pure sterilization-only claims are less common than claims that tie sterilization to purification, filtration, or fermentation hardware.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Single-Use Bioreactor Sterilization covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.